<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The combination of <z:chebi fb="0" ids="35584">purine</z:chebi> analogs with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> is able to produce a synergistic antitumoral effect </plain></SENT>
<SENT sid="1" pm="."><plain>However, the addition of immunosuppressive and DNA-targeting agents might increase <z:chebi fb="0" ids="35584">purine</z:chebi> analog-related complications </plain></SENT>
<SENT sid="2" pm="."><plain>The risk for serious complications was evaluated in 38 patients treated with 2-chloro-2'-<z:chebi fb="0" ids="16335">deoxyadenosine</z:chebi> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CDA</z:e>) and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CP) </plain></SENT>
<SENT sid="3" pm="."><plain>The diagnoses were <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL) in 15, Waldenstr√∂m's <z:e sem="disease" ids="C0024419" disease_type="Neoplastic Process" abbrv="">macroglobulinemia</z:e> in 4, mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in 6, follicular non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) in 10, and other low-grade NHL in 3 patients </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were pretreated (median: 2 lines, range: 1-5) and 23 (61%) were refractory </plain></SENT>
<SENT sid="5" pm="."><plain>The patients received a median of two courses (range: 1-5) of 5.6 mg/m(2) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CDA</z:e>, followed by a median of 200 mg/m(2) CP, for 3 days </plain></SENT>
<SENT sid="6" pm="."><plain>The response rate was 51% [complete remission (CR): 14%, partial remission (PR): 38%] </plain></SENT>
<SENT sid="7" pm="."><plain>Grade 3/4 infections occurred in 16 (42%) patients </plain></SENT>
<SENT sid="8" pm="."><plain>Dose-limiting cytopenias were seen in 22 (58%) patients </plain></SENT>
<SENT sid="9" pm="."><plain>In 12 (32%) patients, autoimmune manifestations developed requiring treatment in most of them </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">Second cancers</z:e> arose in five (13%) patients (<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>/<z:hpo ids='HP_0004808'>acute myelocytic leukemia</z:hpo> in three, <z:e sem="disease" ids="C0242379" disease_type="Neoplastic Process" abbrv="">lung cancer</z:e> in two) </plain></SENT>
<SENT sid="11" pm="."><plain>Multivariate analysis showed that cytopenias, gender (F), prior radiotherapy, and age (&gt;65 years) predicted for the complications seen after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CDA</z:e>-CP </plain></SENT>
<SENT sid="12" pm="."><plain>To conclude, because of the high incidence of complications, caution is warranted in selecting patients with advanced lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> for the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CDA</z:e>-CP protocol </plain></SENT>
</text></document>